175 related articles for article (PubMed ID: 36198437)
21. Novel insights into the SPOP E3 ubiquitin ligase: From the regulation of molecular mechanisms to tumorigenesis.
Li XM; Wu HL; Xia QD; Zhou P; Wang SG; Yu X; Hu J
Biomed Pharmacother; 2022 May; 149():112882. PubMed ID: 35364375
[TBL] [Abstract][Full Text] [Related]
22. Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases.
Zhuang M; Calabrese MF; Liu J; Waddell MB; Nourse A; Hammel M; Miller DJ; Walden H; Duda DM; Seyedin SN; Hoggard T; Harper JW; White KP; Schulman BA
Mol Cell; 2009 Oct; 36(1):39-50. PubMed ID: 19818708
[TBL] [Abstract][Full Text] [Related]
23. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.
Yahata T; Mizoguchi M; Kimura A; Orimo T; Toujima S; Kuninaka Y; Nosaka M; Ishida Y; Sasaki I; Fukuda-Ohta Y; Hemmi H; Iwahashi N; Noguchi T; Kaisho T; Kondo T; Ino K
Cancer Sci; 2019 Apr; 110(4):1279-1292. PubMed ID: 30702189
[TBL] [Abstract][Full Text] [Related]
24. Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy.
Khatoon E; Parama D; Kumar A; Alqahtani MS; Abbas M; Girisa S; Sethi G; Kunnumakkara AB
Life Sci; 2022 Oct; 306():120827. PubMed ID: 35907493
[TBL] [Abstract][Full Text] [Related]
25. Endometrial cancer-associated mutants of SPOP are defective in regulating estrogen receptor-α protein turnover.
Zhang P; Gao K; Jin X; Ma J; Peng J; Wumaier R; Tang Y; Zhang Y; An J; Yan Q; Dong Y; Huang H; Yu L; Wang C
Cell Death Dis; 2015 Mar; 6(3):e1687. PubMed ID: 25766326
[TBL] [Abstract][Full Text] [Related]
26. Phosphorylation and Stabilization of PD-L1 by CK2 Suppresses Dendritic Cell Function.
Zhao X; Wei Y; Chu YY; Li Y; Hsu JM; Jiang Z; Liu C; Hsu JL; Chang WC; Yang R; Chan LC; Qu J; Zhang S; Ying H; Yu D; Hung MC
Cancer Res; 2022 Jun; 82(11):2185-2195. PubMed ID: 35385574
[TBL] [Abstract][Full Text] [Related]
27. Intratumoral Delivery of an Adenoviral Vector Carrying the
Nakagawa S; Serada S; Kakubari R; Hiramatsu K; Sugase T; Matsuzaki S; Matsuzaki S; Ueda Y; Yoshino K; Ohkawara T; Fujimoto M; Kishimoto T; Kimura T; Naka T
Mol Cancer Ther; 2018 Sep; 17(9):1941-1950. PubMed ID: 29891489
[TBL] [Abstract][Full Text] [Related]
28. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
[No Abstract] [Full Text] [Related]
29. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape.
Lu C; Liu Z; Klement JD; Yang D; Merting AD; Poschel D; Albers T; Waller JL; Shi H; Liu K
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326167
[TBL] [Abstract][Full Text] [Related]
30. Cullin 3 and Its Role in Tumorigenesis.
Chen RH
Adv Exp Med Biol; 2020; 1217():187-210. PubMed ID: 31898229
[TBL] [Abstract][Full Text] [Related]
31. G3BP1 modulates SPOP to promote prostate tumorigenesis.
Mukhopadhyay C; Zhou P
Mol Cell Oncol; 2022; 9(1):2030171. PubMed ID: 35252555
[TBL] [Abstract][Full Text] [Related]
32. VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer.
Zong L; Zhou Y; Zhang M; Chen J; Xiang Y
Cancer Immunol Immunother; 2020 Jan; 69(1):33-42. PubMed ID: 31781843
[TBL] [Abstract][Full Text] [Related]
33. LRP5 competes for SPOP binding to enhance tumorigenesis mediated by Daxx and PD-L1 in prostate cancer.
Gan S; Qu F; Zhang X; Pan X; Xu D; Cui X; Hou J
Exp Cell Res; 2024 Jan; 434(1):113857. PubMed ID: 38008278
[TBL] [Abstract][Full Text] [Related]
34. Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
Kim HS; Kim JY; Lee YJ; Kim SH; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
Gynecol Oncol; 2018 Dec; 151(3):414-421. PubMed ID: 30314669
[TBL] [Abstract][Full Text] [Related]
35. Destruction of DDIT3/CHOP protein by wild-type SPOP but not prostate cancer-associated mutants.
Zhang P; Gao K; Tang Y; Jin X; An J; Yu H; Wang H; Zhang Y; Wang D; Huang H; Yu L; Wang C
Hum Mutat; 2014 Sep; 35(9):1142-51. PubMed ID: 24990631
[TBL] [Abstract][Full Text] [Related]
36. Upregulation of programmed death ligand-1 in tumor-associated macrophages affects chemotherapeutic response in ovarian cancer cells.
Jang YS; Kim TW; Ryu JS; Kong HJ; Jang SH; Nam GH; Kim JH; Jeon S
PLoS One; 2023; 18(2):e0277285. PubMed ID: 36757936
[TBL] [Abstract][Full Text] [Related]
37. MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells.
Zuo Y; Zheng W; Liu J; Tang Q; Wang SS; Yang XS
Neoplasma; 2020 Jan; 67(1):93-101. PubMed ID: 31777260
[TBL] [Abstract][Full Text] [Related]
38. Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer.
Yang Y; Xia L; Wu Y; Zhou H; Chen X; Li H; Xu M; Qi Z; Wang Z; Sun H; Cheng X
Cancer Commun (Lond); 2021 Jun; 41(6):511-527. PubMed ID: 33939321
[TBL] [Abstract][Full Text] [Related]
39. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
40. BCLAF1-induced HIF-1α accumulation under normoxia enhances PD-L1 treatment resistances via BCLAF1-CUL3 complex.
Yao B; Lu Y; Li Y; Bai Y; Wei X; Yang Y; Yao D
Cancer Immunol Immunother; 2023 Dec; 72(12):4279-4292. PubMed ID: 37906282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]